Poolbeg Pharma plc published a National Health Executive article highlighting the real-world challenge CRS creates through the need for close monitoring and treatment once it occurs, with Professor Rakesh Popat co-chief investigator of the TOPICAL trial evaluating POLB 001 as a potential oral preventative treatment for CRS in patients with multiple myeloma receiving bispecific antibody therapy.

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. Ticker AIM: POLB